Lutetium-177 PSMA Therapy Now Available at Chong Hua Hospital Mandaue

Chong Hua Hospital Mandaue proudly announces the availability of Lutetium-177 PSMA therapy, a groundbreaking treatment offering renewed hope for those with advanced-stage prostate cancer.

This innovative therapy precisely targets cancer cells, delivering treatment directly while minimizing harm to healthy tissues. Lutetium-177 PSMA therapy holds the potential to significantly improve survival rates and enhance the quality of life for patients facing this challenging disease.

Pioneering Treatment in the Region: Chong Hua Hospital Mandaue is the first in the entire Visayas and Mindanao to offer this advanced therapeutic option, underscoring commitment to bringing the latest medical breakthroughs to the Cebuano community.

This significant addition to the cancer care arsenal reflects Chong Hua Hospital’s ongoing dedication to providing cutting-edge treatments and improving outcomes for prostate cancer patients.

Discover Hope: Chong Hua Hospital encourages everyone to explore the possibilities of Lutetium-177 PSMA therapy to anyone battling prostate cancer. Consult with the resident oncologist, urologist, and nuclear medicine specialist at Chong Hua Hospital Mandaue to learn more about this targeted treatment and embark on a path towards renewed hope and healing.